Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025		Jun. 30, 2024
Segment Reporting Information [Line Items]
Revenues:		$ 14,653	$ 13,283	$ 28,367		$ 28,162
Earnings	[1]	3,044	(103)	5,828		3,318
Depreciation and Amortization	[2]	1,625	1,730	3,243		3,467
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues:	[3]	348	292	622	[2]	567	[2]
Earnings	[1],[3]	(1,799)	(1,985)	(3,220)		(3,992)
Depreciation and Amortization	[2],[3]	73	91	147		177
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Earnings	[1]	(1,211)	(1,307)	(2,421)		(2,615)
Depreciation and Amortization	[2]	1,211	1,307	2,421		2,615
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Earnings	[1]	(338)	(617)	(620)		(1,125)
Depreciation and Amortization	[2]	(2)	1	(3)		2
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[1],[4]	(537)	(2,091)	(1,944)		(2,469)
Depreciation and Amortization	[2],[4]	3	1	7		5
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues:		14,305	12,991	27,746		27,595
Earnings		6,929	5,897	14,033		13,519
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues:	[5]	14,305	12,991	27,746	[2]	27,595	[2]
Earnings	[1],[5]	6,929	5,897	14,033		13,519
Depreciation and Amortization	[2],[5]	$ 339	$ 330	$ 671		$ 667

[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss).

[2] Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

[3] Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above.

[4] Earnings in the first six months of 2025 include, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $670 million (primarily recorded in Restructuring charges and certain acquisition-related costs) and charges for certain legal matters of $564 million recorded in Other (income)/deductions––net. Earnings in the second quarter and the first six months of 2024 included, among other items, restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.2 billion (primarily recorded in Restructuring charges and certain acquisition-related costs). See Notes 3 and 4.

[5] Biopharma’s earnings in the first six months of 2025 reflect a credit to Cost of sales representing a favorable revision of our estimate of accrued royalties. Biopharma’s revenues and earnings in the first six months of 2024 reflected a non-cash favorable product return adjustment of $771 million (see Note 13C). Biopharma’s earnings also include dividend income from our investment in ViiV of $73 million in the second quarter of 2025 and $74 million in the second quarter of 2024, and $111 million in the first six months of 2025 and $135 million in the first six months of 2024 recorded in Other (income)/deductions––net.